News Releases


Aug 26, 2008 FDA Issues Complete Response Letter for Paliperidone Palmitate for the Treatment of Schizophrenia
Aug 21, 2008 FDA Requires Additional Information on Doribax for Treatment of Hospital-Acquired Pneumonia
Aug 11, 2008 Ethicon Endo-Surgery To Acquire SurgRx
Aug 8, 2008 FDA EXTENDS REVIEW TIMELINE FOR USTEKINUMAB BIOLOGIC LICENSE APPLICATION THREE MONTHS
Aug 5, 2008 Ninety-Six Week Data On Tibotec Investigational NNRTI, TMC278, Presented At AIDS 2008
Aug 1, 2008 Veridex Completes Acquisition of Immunicon Corporation Assets
Jul 30, 2008 Johnson & Johnson (China) Investment Co., Ltd. Acquires Beijing Dabao Cosmetics Co., Ltd.
Jul 30, 2008 Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Submits New Drug Application to FDA for Rivaroxaban
Jul 25, 2008 FDA Grants Pediatric Exclusivity for TOPAMAX®
Jul 16, 2008 FDA Advisory Committee Provides Opinion of DORIBAX(TM) for the Treatment of Hospital-Acquired Pneumonia
Jul 15, 2008 Johnson & Johnson Reports 2008 Second-Quarter Results:
Jul 10, 2008 Johnson & Johnson Announces Commitment To Adopt Revised PhRMA Marketing Code for Responsible Interactions With Healthcare Professionals
Jul 8, 2008 Johnson & Johnson to Host Analyst Conference Call on Second-Quarter Results
Jul 1, 2008 OneTouch® PingTM Glucose Management System Cleared by FDA
Jul 1, 2008 ETHICON Receives Offer from One Equity Partners to Purchase Professional Wound Care Business
Jun 30, 2008 Janssen Announces Launch of Authorized Generic for RISPERDAL(R)
Jun 30, 2008 FDA Approves EVOLENCE®, a New Generation Collagen-Based Facial Filler
Jun 27, 2008 FDA Approves CONCERTA(R) (methylphenidate HCI) Extended-release Tablets for Treatment of ADHD (Attention Deficit Hyperactivity Disorder) in Adults
Jun 18, 2008 Johnson & Johnson Nordic AB Acquires Amic
Jun 17, 2008 FDA Advisory Committee Unanimously Recommends Approval of Ustekinumab for Treatment of Moderate To Severe Plaque Psoriasis
Jun 6, 2008 Johnson & Johnson to Participate in 29th Annual Goldman Sachs Global Healthcare Conference
Jun 5, 2008 Johnson & Johnson Reviews Growth Strategies for Medical Devices & Diagnostics and Consumer Businesses
May 30, 2008 Rivaroxaban Superior to U.S.-Approved Dosing Regimen for Enoxaparin in Reducing Venous Blood Clots after Total Knee Replacement Surgery in Pivotal Phase III Trial
May 29, 2008 Johnson & Johnson to Host Medical Devices & Diagnostics and Consumer Business Review
May 15, 2008 Johnson & Johnson to Participate in Citi's Global Healthcare Conference
May 13, 2008 Biosense Webster Presents ''Complete Ablation Solutions'' to Electrophysiologists at Heart Rhythm 2008
May 13, 2008 State-of-the-Art Cobalt Chromium Bare Metal Stent Now Available in Europe
May 9, 2008 New Data From Phase 3 Study Suggests Tapentadol Immediate Release Effective For Acute Pain From Common Foot Surgery
May 9, 2008 New Study Suggests Tapentadol IR For Acute Pain Is Associated With Improved Gastrointestinal Tolerability Compared To Oxycodone IR
May 9, 2008 Results Of Phase 3 Study Show Tapentadol Ir Relieves Acute Pain And Offers Favorable Gastrointestinal Tolerability Profile
May 7, 2008 Johnson & Johnson to Provide Webcast Presentation of Tapentadol Phase 3 Clinical Data Presented at American Pain Society's Annual Meeting
Apr 29, 2008 Johnson & Johnson to Participate in Deutsche Bank Health Care Conference
Apr 25, 2008 Johnson & Johnson to Participate in Morgan Stanley Conference
Apr 24, 2008 Johnson & Johnson Announces Dividend Increase of 10.8%
Apr 22, 2008 Johnson & Johnson to Webcast Annual Meeting of Shareholders
Apr 15, 2008 Johnson & Johnson Reports 2008 First-Quarter Results:
Apr 11, 2008 Ortho Biotech Oncology Research & Development Unites Johnson & Johnson Biopharmaceutical Oncology R&D Assets
Apr 9, 2008 NEJM Study Demonstrates Carotid Stenting with Embolic Protection is Comparable to Surgery
Apr 8, 2008 Johnson & Johnson to Host Analyst Conference Call on First-Quarter Results
Apr 4, 2008 Data From Ortho Biotech-Sponsored Studies To Be Presented At National Kidney Foundation 2008 Spring Clinical Meetings
Apr 1, 2008 First New NNRTI in Nearly a Decade to Benefit Canadians with HIV/AIDS
Mar 30, 2008 Three Year Follow-up Data Suggest Better Outcomes Were Maintained with the CYPHER(R) Sirolimus-Eluting Coronary Stent Compared to Brachytherapy in Patients with In-Stent Reblockage
Mar 28, 2008 Ortho-Clinical Diagnostics Receives FDA Approval for New HIV Test
Mar 27, 2008 Clinical Trial Begins for Innovative Drug-Eluting Stent with Unique Reservoir Technology
Mar 27, 2008 Ethicon Endo-Surgery Submits Application to FDA for Approval of the Sedasys™ System - The First Computer-Assisted Personalized Sedation System
Mar 21, 2008 Relief "In Sight" For Allergy Sufferers
Mar 19, 2008 Centocor, Inc. And Schering-Plough Submit Application Requesting Approval Of Golimumab In Europe For The Treatment Of Rheumatoid Arthritis, Psoriatic Arthritis And Ankylosing Spondylitis
Mar 18, 2008 FDA Issues Approvable Letter for Ceftobiprole for Treatment of Complicated Skin Infections
Mar 17, 2008 Cordis Corporation Receives U.S. Food and Drug Administration Clearance for S.M.A.R.T. Nitinol Stent Transhepatic Biliary System for 120 mm and 150 mm Lengths
Mar 17, 2008 Ortho Biotech Statement on U.S. Food and Drug Administration Oncologic Drugs Advisory Committee Vote
Mar 13, 2008 Johnson & Johnson to Participate in the 28th Annual Cowen & Company Health Care Conference
Mar 11, 2008 Totality of Available Data Reaffirms PROCRIT® (Epoetin alfa) Safe and Effective When Used Appropriately As Labeled to Treat Chemotherapy-Induced Anemia
Mar 11, 2008 Johnson & Johnson to Participate in Lehman Brothers Eleventh Annual Global Healthcare Conference
Mar 7, 2008 Ortho Biotech Modifies Prescribing Information for PROCRIT® (Epoetin alfa)
Mar 6, 2008 FDA Extends Review Timeline for Additional Indication for Antibiotic DORIBAX(TM)
Feb 27, 2008 FDA CLEARS CELLSEARCH™ CIRCULATING TUMOR CELL TEST
Feb 27, 2008 DePuy to Host Analyst Meeting
Feb 12, 2008 PRICARA™ RECALLS 25 mcg/hr DURAGESIC® (fentanyl transdermal system) CII PAIN PATCHES
Feb 7, 2008 New 48-Week Efficacy and Safety Data Presented for Intelencetm (Etravirine) As Part of HIV Combination Therapy
Feb 4, 2008 Promising Phase 3 Data for Ustekinumab (Cnto 1275) in Long-Term Improvement of Chronic Plaque Psoriasis
Feb 4, 2008 Centocor Announces Ustekinumab Biologic License Application Accepted For Filing By FDA
Feb 4, 2008 Study Suggests Risperidone Long-Acting Injection Combined with Standard Treatment Helped Delay Time to Relapse in Patients with Bipolar Disorder
Jan 23, 2008 New Drug Application Submitted to FDA for Investigational Analgesic Tapentadol Immediate Release Tablets
Jan 22, 2008 Johnson & Johnson Reports Fourth-Quarter and Full-Year 2007 Results
Jan 18, 2008 FDA Approves INTELENCE(TM) (etravirine) for HIV Combination Therapy
Jan 15, 2008 Johnson & Johnson to Review Fourth-Quarter and Full-Year 2007 Financial Results
Jan 14, 2008 IONSYS™, the highly innovative needle-free system for the management of acute post-operative pain, available in Germany, the UK and Ireland
Jan 7, 2008 Court of Appeals Upholds Verdicts in Favor of Cordis Corporation on Patents Infringed by Medtronic, Inc. and Boston Scientific Corporation
Dec 21, 2007 Supplemental New Drug Application for PREZISTA™ Submitted to U.S. Food and Drug Administration
Dec 21, 2007 Centocor Inc., Schering-Plough Corporation Revise Agreement Covering REMICADE®, Golimumab
Dec 21, 2007 Submission of Marketing Authorisation Application for VELCADE® (bortezomib) in Europe
Dec 12, 2007 INVEGA™ Shows Favorable Long-Term Safety Profile in a One Year Study of Patients With Schizophrenia
Dec 10, 2007 Three Phase III Trials Show Rivaroxaban Outperformed Enoxaparin in Preventing Venous Thromboembolism After Major Orthopedic Surgery
Dec 8, 2007 Pivotal Phase III Data Showed Rivaroxaban Was Statistically Superior to Enoxaparin in Preventing Venous Thromboembolism (VTE) in Patients Following Hip Replacement Surgery
Dec 4, 2007 Centocor and Janssen-Cilag announced the submission of the US and European filings for ustekinumab (CNTO 1275) for the treatment of adult patients with chronic moderate to severe plaque psoriasis.
Nov 16, 2007 FDA Approves the Allergy Treatment Zyrtec® for Use Without a Prescription
Nov 15, 2007 Johnson & Johnson Announces Changes to Accelerate Growth
Nov 9, 2007 New Phase III Trial Results for Rivaroxaban to be Presented at the 49th Annual Meeting of the American Society of Hematology
Nov 6, 2007 Johnson & Johnson to Present at the Credit Suisse 2007 Healthcare Conference
Nov 5, 2007 Pooled Analysis Of Long-Term Data Suggests CYPHER® Sirolimus-Eluting Coronary Stent Provides Sustained Clinical Benefits In Patients With Coronary Artery Disease Compared To Bare Metal Stents
Nov 1, 2007 Johnson & Johnson to Host Analyst Meeting to Discuss Three Late-Stage Pipeline Compounds Presented at American College of Rheumatology (ACR) Conference
Oct 29, 2007 Johnson & Johnson Pharmaceutical Research & Development Submits New Drug Application for Paliperidone Palmitate
Oct 26, 2007 New Study of Concerta(R) Showed Significant Improvement of ADHD Symptom Management in Adults Compared to Placebo
Oct 23, 2007 Adoption of Drug-Eluting Stents Associated With Lower Health Care Costs and Improved Clinical Outcomes
Oct 23, 2007 Next Generation New Devices to Treat Clogged Neck Arteries Launched in U.S. and Europe
Oct 22, 2007 New Long-Term Data Suggest Clinical Differences in Safety and Efficacy Between CYPHER® Sirolimus-Eluting Coronary Stent and Taxus Stent
Oct 21, 2007 New Study Shows Excellent Outcomes for CYPHER® Sirolimus-Eluting Coronary Stent in Treatment of Completely Blocked Coronary Arteries
Oct 17, 2007 Cordis Corporation Announces Clinical Studies And Events At TCT 2007
Oct 16, 2007 Johnson & Johnson Launches Global Diabetes Institute to Provide State-of-The- Art Education, Training to Health Professionals
Oct 16, 2007 Johnson & Johnson Reports 2007 Third-Quarter Results: Sales of $15.0 Billion Increased 12.7%; EPS was $.88, Including Special Charges; Excluding Special Charges, EPS was $1.06 *
Oct 15, 2007 FDA Approves DORIBAX™ for the Treatment of Complicated Intra-Abdominal and Complicated Urinary Tract Infections
Oct 13, 2007 INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients
Oct 11, 2007 McNeil Consumer Healthcare Is Voluntarily Withdrawing Infants' Cough And Cold Products: CONCENTRATED TYLENOL® INFANTS' DROPS PLUS COLD, CONCENTRATED TYLENOL® INFANTS' DROPS PLUS C
Oct 10, 2007 Johnson & Johnson to Host Analyst Meeting to Discuss Third-Quarter Financial Results and Review Its Medical Device & Diagnostics Business
Oct 9, 2007 New HARMONIC FOCUS™ Provides Advantages in Surgical Efficiency, Performance and Patient Outcomes
Oct 8, 2007 New Data Show Ceftobiprole as Effective as Combination Therapy in Treating Patients with Diabetic Foot Infections
Oct 8, 2007 Topline Findings from Comparative Analysis of INVEGA(TM) and Quetiapine in Schizophrenia to be Postered at the 20th Annual U.S. Psychiatric and Mental Health Congress
Oct 3, 2007 Ortho-Clinical Diagnostics Introduces Improved Sensitivity Troponin I Assay To Help Diagnose Heart Attack, Heart Damage
Sep 27, 2007 Statement of DePuy Orthopaedics, Inc. Regarding Agreement with U.S. Attorney's Office
Sep 25, 2007 Pivotal Ustekinumab (CNTO 1275) Phase 3 Data to Debut at World Congress of Dermatology Meeting
Sep 20, 2007 FDA Accepts New Drug Application For Priority Review Of Investigational HIV Treatment TMC125
Sep 20, 2007 Johnson Statement on Litigation with the American Red Cross
Sep 18, 2007 New Phase 3 Study In Treatment-Naïve Adults With HIV Evaluates Efficacy And Safety Of Once-Daily PREZISTA™/Ritonavir Vs. Kaletra® As Part Of HIV Combination Therapy
Sep 18, 2007 New Data Show Ceftobiprole as Effective as Combination Therapy in Treating Patients With Complicated Skin Infections, Including MRSA
Sep 18, 2007 New Data Show Doripenem as Effective as Commonly Used Therapies in Treating Hospital-Acquired Pneumonias
Sep 17, 2007 FDA Approves LEVAQUIN® Short-Course Therapy for Treatment of Complicated Urinary Tract Infections and Acute Pyelonephritis
Sep 13, 2007 Largest Study To Date Finds Drug-Eluting Stents And Bare-Metal Stents Yield Similarly Low Mortality Rates
Sep 12, 2007 Ortho Biotech Reiterates Confidence in PROCRIT® (Epoetin alfa) Safety and Efficacy When Used According to Label
Sep 11, 2007 Ortho Biotech Reiterates Confidence in PROCRIT® (Epoetin alfa) Safety and Efficacy When Used According to Label
Sep 5, 2007 Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
Sep 4, 2007 Johnson & Johnson to Participate in Bear Stearns 20th Annual Healthcare Conference
Sep 4, 2007 Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
Sep 3, 2007 Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
Aug 22, 2007 FDA Approves RISPERDAL® to Treat Adolescents With Schizophrenia and Children and Adolescents With Bipolar Mania
Aug 8, 2007 Johnson & Johnson Statement on Civil Complaint Against The American National Red Cross and Commercial Licensees
Jul 31, 2007 Johnson & Johnson Plans to Improve Overall Cost Structure, While Continuing to Invest in Opportunities for Sustained Profitable Growth
Jul 19, 2007 Ortho-McNeil, Inc., Settles Patent Infringement Litigation Against Par/Kali
Jul 18, 2007 New Drug Application for Investigational HIV Treatment TMC125 Submitted to U.S. Food and Drug Administration
Jul 17, 2007 Johnson & Johnson Reports 2007 Second-Quarter Results: Sales Increase of 13.2% and EPS increase of 10.5% Versus a Year Ago; Excluding Special Charges in 2006, EPS increased 7.1%*
Jul 17, 2007 FDA Approves First Gene-Based Test To Detect The Spread Of Breast Cancer Into Lymph Nodes
Jul 11, 2007 Johnson & Johnson to Host Analyst Conference Call on Second-Quarter Results
Jul 9, 2007 Johnson & Johnson Announces $10 Billion Share Repurchase Program
Jul 8, 2007 Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Jul 6, 2007 TMC125 Demonstrates Significant Efficacy in Treatment-Experienced Patients with NNRTI Resistance in Phase III trials
Jul 6, 2007 New PREZISTA® Phase III Study meets primary objective of non-inferiority and secondary objective of superiority in virologic response vs. KALETRA® in treatment-experienced HIV patients
Jun 28, 2007 INVEGA™ Receives Marketing Authorization In European Union For Treatment Of Schizophrenia
Jun 28, 2007 World Council of Optometry Awards ACUVUE(R) ADVANCE(TM), ACUVUE(R) OASYS(TM) Brands With Global Seal of Acceptance for UV Absorbing Contact Lenses
Jun 21, 2007 FDA Issues Approvable Letter for RISPERDAL(R) to Treat Adolescents with Schizophrenia and Children and Adolescents with Bipolar Mania
Jun 14, 2007 Johnson & Johnson Invites Nominations for the 2008 Dr. Paul Janssen Award for Biomedical Research
Jun 14, 2007 Cordis Corporation Resolves Corporate Warning Letter
Jun 12, 2007 William D. Perez of Wm. Wrigley Jr. Company Appointed to Johnson & Johnson Board of Directors
Jun 7, 2007 New Balloon Catheter Available Worldwide for Carotid and Renal Angioplasty Procedures
Jun 7, 2007 Johnson & Johnson Highlights Growth Strategies for Pharmaceutical and Consumer Businesses
Jun 6, 2007 New Drug Application Submitted for Investigational Antibiotic Doripenem
Jun 6, 2007 VISTAKON(R) Launches Electronic Contact Lens Reminder Service to Help Improve Contact Lens Compliance
Jun 4, 2007 New Study Suggests Better Patient Outcomes with CYPHER(R) Sirolimus-Eluting Coronary Stent than with Taxus Stent in Real-World Clinical Settings
May 29, 2007 Johnson & Johnson To Host Pharmaceutical and Consumer Business Review
May 22, 2007 CYPHER(R) Sirolimus-Eluting Coronary Stent Had Similar Results to Bypass Surgery and Better Outcomes Than Bare Metal Stents in Subgroup Analysis of Diabetic Patients With Multivessel Coronary Disease
May 21, 2007 Johnson & Johnson to Participate in Bank of America 2007 Health Care Conference
May 18, 2007 New Drug Application Submitted For Novel Investigational Antibiotic Ceftobiprole
May 16, 2007 Johnson & Johnson to Participate in Citigroup's Global Healthcare Conference
May 16, 2007 Cordis To Host Analyst Meeting At EuroPCR 2007
May 11, 2007 Southern District Court of New York Rules Patent for ACIPHEX® Enforceable
May 7, 2007 Conor Medsystems, LLC Reports COSTAR II Pivotal Drug-Eluting Stent Trial Conclusions
May 4, 2007 Ortho-Clinical Diagnostics, Inc. Issues Voluntary, Nationwide Recall for Cardiac Marker
Apr 27, 2007 Johnson & Johnson to Participate in Morgan Stanley Conference
Apr 26, 2007 Johnson & Johnson Announces Dividend Increase of 10.7%
Apr 19, 2007 Johnson & Johnson to Host Annual Meeting of Shareholders
Apr 19, 2007 Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Breaks Ground on New Facility
Apr 17, 2007 Johnson & Johnson Reports 2007 First-Quarter Results: Sales Increase of 15.7% and EPS of $.88 Versus $1.10 a Year Ago; Excluding Special Items, EPS was $1.16, an increase of 17.2% *
Apr 11, 2007 Johnson & Johnson to Host Analyst Conference Call on First-Quarter Results
Mar 26, 2007 Two-Year Patient Registry Results Support Safety and Efficacy of CYPHER(R) Sirolimus-Eluting Coronary Stent in 'Real World' Uses
Mar 20, 2007 Cordis Corporation to Emphasize Commitment to Interventional Cardiology at ACC.07
Mar 13, 2007 Johnson & Johnson to Participate in Lehman Brothers Tenth Annual Global Healthcare Conference
Mar 12, 2007 Johnson & Johnson Receives Subpoenas
Mar 7, 2007 Johnson & Johnson to Participate in the 27th Annual Cowen & Company Health Care Conference
Feb 12, 2007 Johnson & Johnson Statement on Voluntary Disclosure
Feb 1, 2007 Johnson & Johnson Completes Acquisition of Conor Medsystems, Inc.
Jan 23, 2007 Johnson & Johnson Reports Fourth-Quarter and Full-Year 2006 Results
Jan 17, 2007 Johnson & Johnson to Review Fourth-Quarter and Full-Year 2006 Financial Results
Dec 20, 2006 Johnson & Johnson Completes Acquisition of Pfizer Consumer Healthcare
Dec 12, 2006 Johnson & Johnson Acquisition of Pfizer Consumer Healthcare Receives Clearance from U.S. Federal Trade Commission (FTC)
Dec 11, 2006 Analysis From Real-World Drug Administration Data Suggests Lower Drug Cost For PROCRIT(R) (Epoetin Alfa) in Outpatient Setting
Nov 27, 2006 Winter Sun's Rays Can Be Damaging to Eyes
Nov 16, 2006 Johnson & Johnson Announces Definitive Agreement to Acquire Conor Medsystems, Inc.
Oct 24, 2006 Cordis Corporation To Study Impact Of Contributing Factors To Stent Thrombosis In Expansion Of 30,000-Stent Patient Registry
Oct 24, 2006 U.S. District Court Grants Request for Preliminary Injunction to Ortho-McNeil Neurologics, Inc. for TOPAMAX(R)
Oct 17, 2006 Johnson & Johnson Reports 2006 Third-Quarter Results: Sales Increase of 7.9% and EPS of $.94 Versus $.85 a Year Ago; Excluding In-Process Research and Development Charges, EPS Increased 15.3% *
Oct 16, 2006 Cordis to Host Analyst Meeting at TCT Conference
Oct 16, 2006 U.S. District Court Upholds RISPERDAL(R) Patent
Oct 10, 2006 Johnson & Johnson to Host Analyst Conference Call on Third-Quarter Results
Oct 6, 2006 Robert J. Darretta to Retire as Vice Chairman and CFO of Johnson & Johnson
Sep 28, 2006 As U.S. Population Swells to 300 Million, New Survey Examines The Evolution of Motherhood
Sep 13, 2006 Johnson & Johnson to Participate in Merrill Lynch Conference
Sep 12, 2006 RNAi Pioneer Craig Mello Named Inaugural Winner of the Dr. Paul Janssen Award for Biomedical Research
Sep 7, 2006 Johnson & Johnson to Participate in the Bear Stearns 19th Annual Health Care Conference
Aug 29, 2006 Johnson & Johnson to Host Medical Devices & Diagnostics Business Review
Jul 25, 2006 VISTAKON to Introduce New 1-DAY ACUVUE(R) MOIST(TM) Brand Contact Lenses In U.S. - A Breakthrough in Comfort
Jul 21, 2006 Update on FDA Psychopharmacologic Drugs Advisory Committee Meeting for Sept. 7 on Paliperidone Extended-Release Tablets
Jul 18, 2006 Johnson & Johnson Reports 2006 Second-Quarter EPS Increase of 10.5% on Sales Increase of 4.7%
Jul 12, 2006 Investigational Drug Paliperidone ER Significantly Delayed Symptom Recurrence In Clinical Study of Patients With Schizophrenia
Jul 12, 2006 Johnson & Johnson to Host Analyst Meeting to Discuss Second-Quarter Financial Results; Review Pharmaceuticals Business/Pipeline and the Planned Acquisition of Pfizer Consumer Healthcare
Jul 11, 2006 New Survey Reveals Many Contact Lens Wearers Find Their Lenses Uncomfortable, Disruptive When Experiencing Eye-Allergy Symptoms
Jul 6, 2006 2006 NBA Champion Alonzo Mourning Raises Awareness About Kidney Disease
Jun 30, 2006 Janssen Pharmaceutica Announces Collaboration with Vertex Pharmaceuticals to Develop and Commercialize VX-950 for Treatment of Hepatitis C
Jun 26, 2006 Johnson & Johnson to Acquire Pfizer Consumer Healthcare; Combination Creates World's Premier Consumer Health Care Company
Jun 23, 2006 American Optometric Association Awards ACUVUE ADVANCE, ACUVUE OASYS Brands With Seal of Acceptance for UV Absorbing Contact Lenses
Jun 8, 2006 Johnson & Johnson to Participate in Goldman Sachs Conference
Jun 1, 2006 Update On Regulatory Filing Plans for Investigational Compound Trabectedin in Soft Tissue Sarcoma
May 23, 2006 Clinical Study of Investigational Drug Paliperidone ER Demonstrated Efficacy and Tolerability in the Treatment of Patients With Schizophrenia
May 16, 2006 Physicians Now Have a New Treatment Option for Patients With a Common Vascular Disease Affecting the Legs
May 11, 2006 District Court Issues Two Decisions Regarding Patent Litigation Between Cordis Corporation and Boston Scientific
May 11, 2006 Johnson & Johnson to Participate in the Banc of America Securities Health Care Conference 2006
May 10, 2006 Pharmaceutical Operating Companies of Johnson & Johnson Continue Patient Assistance for Eligible Medicare Beneficiaries
May 9, 2006 ETHICON, Inc. Completes Acquisition of Vascular Control Systems, Inc.
May 5, 2006 Janssen-Cilag Submits Marketing Authorization Application in Europe for New Treatment for Schizophrenia
Apr 27, 2006 Johnson & Johnson to Participate in Morgan Stanley Conference
Apr 27, 2006 Johnson & Johnson Announces Dividend Increase of 13.6%
Apr 24, 2006 Johnson & Johnson to Host Annual Meeting of Shareholders
Apr 18, 2006 Johnson & Johnson Reports 2006 First-Quarter EPS Rose 17.0% on Sales Increase of 1.2%
Apr 11, 2006 Johnson & Johnson to Host Analyst Conference Call on First-Quarter Results
Mar 31, 2006 Ortho-Clinical Diagnostics Issues a Voluntary Product Recall for VITROS(R) Immunodiagnostic Products Signal Reagent
Mar 28, 2006 Johnson & Johnson Presents $100,000 Grant for SF Disaster Preparedness & Neighborhood Emergency Response Training (NERT) Program
Mar 23, 2006 Johnson & Johnson Consumer France SAS to Acquire Groupe Vendome SA
Mar 20, 2006 Increased Use of Computers, Portable Gadgets Leading to More Visual Fatigue And Discomfort
Mar 8, 2006 Johnson & Johnson Announces Stock Repurchase Program
Mar 1, 2006 Johnson & Johnson To Participate In The 26th Annual Cowen & Company Health Care Conference
Feb 23, 2006 Silver Medalists Belbin & Agosto See Gold With ACUVUE® OASYS™ Brand
Feb 17, 2006 Johnson & Johnson Completes Acquisition of Animas Corporation
Feb 13, 2006 Charles Prince of Citigroup Elected to Johnson & Johnson Board of Directors
Feb 1, 2006 Johnson & Johnson to Participate in Merrill Lynch Conference
Jan 30, 2006 European Commission Approves IONSYS(TM) (Fentanyl HCl Iontophoretic Transdermal System)
Jan 25, 2006 Johnson & Johnson Statement Regarding Guidant Corporation
Jan 24, 2006 Johnson & Johnson Reports Full-Year and Fourth-Quarter 2005 Results
Jan 19, 2006 DePuy Orthopaedics Concludes Acquisition of Hand Innovations LLC
Jan 18, 2006 Johnson & Johnson to Review Fourth-Quarter and Full-Year 2005 Financial Results
Jan 17, 2006 Johnson & Johnson Statement Regarding Guidant Corporation Acquisition
Jan 13, 2006 Guidant Corporation and Johnson & Johnson Announce New Definitive Acquisition Agreement
Jan 11, 2006 Guidant Corporation and Johnson & Johnson Announce New Definitive Acquisition Agreement
Jan 8, 2006 Johnson & Johnson Reaffirms Commitment to Guidant Acquisition
Jan 3, 2006 Scios Submits Interim Report to FDA on NATRECOR®(nesiritide) PROACTION Trial
Dec 28, 2005 Johnson & Johnson and Guidant Corporation Proposed Merger Registration Statement Declared Effective
Dec 21, 2005 Personal Products Company Completes Acquisition of REMBRANDT(R) Brand From The Gillette Company
Dec 16, 2005 Johnson & Johnson Announces Definitive Agreement to Acquire Animas Corporation, an Insulin Delivery Company
Dec 14, 2005 Potential New Treatment for Patients with Schizophrenia
Dec 8, 2005 Contact Lens Made With New Silicone Hydrogel Material May Help Reduce Most Frequently Reported Lens Problems, Study Shows
Dec 6, 2005 Johnson & Johnson Files Form S-4 Registration Statement Regarding Acquisition of Guidant Corporation
Dec 1, 2005 ALZA Corporation Modifies U.S. Clinical Development Program for OROS Hydromorphone (AP-77)
Nov 30, 2005 New Drug Application Submitted for Potential New Treatment for Schizophrenia
Nov 28, 2005 ALZA Corporation Resubmits U.S. New Drug Application for IONSYS(TM) (Fentanyl HCl Patient-Activated Transdermal System)
Nov 22, 2005 Johnson & Johnson to Participate in Fifth Annual Merrill Lynch Med Tech Fundamentals Conference
Nov 15, 2005 Johnson & Johnson and Guidant Corporation Announce Revised Acquisition Agreement with Net Value of $19 Billion
Nov 10, 2005 Study Finds Patients with Moderate to Severe Chronic Kidney Disease Go Undiagnosed
Nov 7, 2005 Johnson & Johnson Statement Regarding Guidant Corporation Civil Suit
Nov 3, 2005 Johnson & Johnson to Participate in CIBC World Markets Sixteenth Annual Health Care Conference
Nov 2, 2005 Johnson & Johnson Receives FTC Clearance of Proposed Acquisition of Guidant Corporation and Provides Update on Transaction in Light of Guidant Recall Events
Oct 26, 2005 Tibotec Announces U.S. Expanded Access Program for TMC114
Oct 24, 2005 Personal Products Company to Acquire Rembrandt Brand from The Gillette Company
Oct 18, 2005 Johnson & Johnson Reports 2005 Third-Quarter EPS Rose 11.5% on Sales Increase of 6.6%
Oct 14, 2005 European Authorities Recommend Approval for IONSYS(TM)
Oct 12, 2005 Johnson & Johnson to Host Analyst Conference Call on Third-Quarter Results
Sep 28, 2005 Cordis Corporation Acquires LuMend, Inc.
Sep 26, 2005 Basketball Star Alonzo Mourning Spreads the Word About Kidney Disease
Sep 22, 2005 Head-to-Head Study of Treatments for Chemotherapy-Related Anemia Published in The Oncologist
Sep 7, 2005 Johnson & Johnson to Participate in the 18th Annual Bear Stearns 2005 Health Care Conference
Sep 2, 2005 Johnson & Johnson Advised by Canadian Competition Bureau on Proposed Acquisition of Guidant Corporation
Aug 25, 2005 Johnson & Johnson Announces European Commission Clearance of Guidant Acquisition
Aug 11, 2005 Newly Published Study Evaluates Extended Dosing Regimens of PROCRIT® (Epoetin alfa) as Maintenance Treatment for Patients with Anemia from Chronic Kidney Disease
Aug 2, 2005 Johnson & Johnson Adopts PhRMA Guidelines on Direct-to-Consumer Advertising
Jul 26, 2005 Johnson & Johnson Becomes Official Partner of Beijing 2008 Olympic Games, Torino 2006 Olympic Winter Games, USOC and National Olympic Teams
Jul 20, 2005 Scios Inc. Receives Subpoena on NATRECOR(R) (Nesiritide)
Jul 19, 2005 Scios Inc. Announces Redemption of 5.50% Debentures Due August 2009
Jul 19, 2005 Johnson & Johnson Reports 2005 Second-Quarter Sales Increase of 11.1% and EPS of $.89 Versus $.82 a Year Ago; Excluding In-Process Research and Development Charges and Revised Tax Impact of American Jobs Creation Act, EPS Increased 13.4%*
Jul 12, 2005 Johnson & Johnson to Host Analyst Conference Call on Second Quarter Results
Jul 1, 2005 Cordis to Ask Judge to Overturn Patent Verdict
Jun 30, 2005 Cordis Endovascular Launches PALMAZ(R) BLUE(TM) Transhepatic Biliary Cobalt Chromium Stent in U.S.
Jun 30, 2005 Johnson & Johnson Completes Acquisition of Peninsula Pharmaceuticals, Inc.
Jun 21, 2005 Jury Finds Cordis Patents Infringed by Boston Scientific Stents
Jun 17, 2005 Johnson & Johnson Statement Regarding Guidant Transaction
Jun 9, 2005 Cordis Corporation to Appeal Court Ruling
Jun 3, 2005 Johnson & Johnson Completes Acquisition of CLOSURE Medical Corporation
Jun 2, 2005 New Online Greeting Card Promotes Awareness of Chronic Kidney Disease During Hispanic Health Month
Jun 2, 2005 World-Renowned Chef and Cancer Survivor Biba Caggiano Visits Long Island Hospitals to Help Cancer Patients Find Strength for Living
May 24, 2005 Johnson & Johnson Statement Regarding Guidant Transaction
May 19, 2005 Johnson & Johnson to Host Pharmaceutical Research and Development Review
May 18, 2005 CYPHER(R) Sirolimus-eluting Coronary Stent Clinical Data to Be Featured at 2005 EuroPCR
May 17, 2005 Online Greeting Card Series Honors Women Affected by Chronic Kidney Disease
May 15, 2005 Head-to-Head Study of Treatments for Chemotherapy-Related Anemia Found Patients Treated With Procrit(R) Demonstrated Greater Increase in Red Blood Cell Levels, Required Less Transfused Blood
Apr 29, 2005 Johnson & Johnson to Participate in Morgan Stanley Conference
Apr 29, 2005 World-Renowned Chef and Cancer Survivor Biba Caggiano Shares Ingredients for Helping Cancer Patients Find Strength for Living
Apr 28, 2005 Johnson & Johnson Announces Dividend Increase of 15.8%
Apr 27, 2005 New ACUVUE(R) ADVANCE(TM) Brand Contact Lenses for ASTIGMATISM Offer Consistent All-Day Vision, Comfort in The 'Blink Of An Eye'
Apr 26, 2005
Apr 22, 2005 Johnson & Johnson Proposed Acquisition of Guidant Corporation Enters Second Phase Review by European Commission
Apr 21, 2005 Johnson & Johnson to Host Annual Meeting of Shareholders
Apr 20, 2005 CYPHER(R) Sirolimus-Eluting Coronary Stent Receives FDA Approval for MRI Scans Immediately Following Implantation
Apr 19, 2005 Johnson & Johnson - The World's Most Broadly Based Health Care Company Reports 2005 First-Quarter EPS Rose 16.9% on Sales Increase of 11.0%
Apr 19, 2005 Johnson & Johnson Announces Agreement to Acquire Peninsula Pharmaceuticals, Inc.
Apr 13, 2005 Johnson & Johnson to Host Analyst Conference Call on First Quarter Results
Apr 5, 2005 U.S. Pharmaceutical and Biotechnology Companies of Johnson & Johnson Participate in Partnership for Prescription Assistance
Apr 4, 2005 Johnson & Johnson Completes Acquisition of TransForm Pharmaceuticals, Inc.
Mar 30, 2005 DePuy Orthopaedics, Inc. Receives Subpoena
Mar 24, 2005 Johnson & Johnson and Guidant Corporation Proposed Merger Registration Declared Effective
Mar 14, 2005 Michael M.E. Johns, M.D. of Emory University Nominated for Election to the Johnson & Johnson Board of Directors
Mar 9, 2005 Johnson & Johnson to Acquire TransForm Pharmaceuticals
Mar 6, 2005 Arts II Clinical Study Shows Promising Results for the Cypher(R) Sirolimus-Eluting Coronary Stent In Patients With Multi-Vessel Disease
Mar 6, 2005 REALITY Trial Data Suggest Drug-Eluting Stents Differ Significantly in Rate of Blood Clot Formation-Stent Thrombosis
Mar 4, 2005 Johnson & Johnson and CLOSURE Medical Corporation Announce Acquisition Agreement
Mar 4, 2005 Multimedia Available: Basketball Star Alonzo Mourning Reaches Out to Fellow Kidney Disease Patients with New Series of Online Greeting Cards
Mar 1, 2005 Cordis to Host Analyst Meeting to Review REALITY Trial Results
Feb 28, 2005 Multimedia Available: KidneyResource.com: A New Internet Gateway to Science-Based Information About Chronic Kidney Disease
Feb 24, 2005 CYPHER(R) Sirolimus-Eluting Coronary Stent to Be Featured in Late-Breaking Clinical Trial Presentations at 2005 American College of Cardiology Scientific Session
Feb 24, 2005 CYPHER(R) Sirolimus-Eluting Coronary Stent to Be Featured in Late-Breaking Clinical Trial Presentations at 2005 American College of Cardiology Scientific
Feb 18, 2005 Johnson & Johnson and Guidant Corporation Will Respond to Federal Trade Commission's Request For Information
Feb 14, 2005 Stories of Survival and Hope Mark the One Million Patient Milestone For the CYPHER(R) Sirolimus-eluting Coronary Stent
Feb 3, 2005 Johnson & Johnson to Participate in Merrill Lynch Conference
Jan 25, 2005 Johnson & Johnson - The World's Most Broadly Based Health Care Company 2004 Fourth-Quarter Sales Increased 13.3% Tax Impact of American Jobs Creation Act Reduced Fourth-Quarter Earnings 2004 Full Year EPS Rose 18.3% on Sales Increase of 13.1%
Jan 24, 2005 Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Completes Submission of Tipifarnib NDA to FDA Continuous Marketing Application Pilot-1 Program
Jan 21, 2005 Health Authorities Reviewing Safety Data from Investigational Study Involving REMINYL(R) (galantamine hydrobromide)
Jan 18, 2005 Johnson & Johnson To Review Fourth-Quarter Results
Jan 12, 2005 Christine A. Poon Appointed a Vice Chairman of Johnson & Johnson